Valneva SE (VALN) Current Assets (2020 - 2026)
Valneva SE (VALN) posted Current Assets of $235.8 million for Q1 2026, down 8.96% sequentially from $259.0 million in Q4 2025, and down 21.89% YoY from $301.9 million in Q1 2025.
Analysis
Valneva SE (VALN) Current Assets (2020 - 2026) Analysis & Trends
Valneva SE has reported Current Assets for 7 years, with the latest figure at $235.8 million in Q1 2026.
- Quarterly Current Assets fell 21.89% year-over-year to $235.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.8 million (down 21.89% YoY) and the FY2025 annual result came in at $259.0 million, down 19.96% from the prior year.
- Current Assets fell to $235.8 million in Q1 2026 per VALN's latest filing, from $259.0 million in the prior quarter.
- Over five years, Current Assets peaked at $611.7 million in Q1 2022 and troughed at $235.8 million in Q1 2026.
- A 5-year average of $364.3 million and a median of $332.7 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets plunged 35.35% in 2022, then gained 12.99% in 2024.
- Over 5 years, Current Assets stood at $433.3 million in 2022, then sank by 34.73% to $282.8 million in 2023, then rose by 12.99% to $319.5 million in 2024, then dropped by 18.93% to $259.0 million in 2025, then slipped by 8.96% to $235.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $235.8 million, $259.0 million, and $313.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 259.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 259.06 Mn |
| Mar 31, 2026 | 235.83 Mn |
| Dec 31, 2025 | 259.05 Mn |
| Sep 30, 2025 | 313.69 Mn |
| Jun 30, 2025 | 322.29 Mn |
| Mar 31, 2025 | 301.94 Mn |
| Dec 31, 2024 | 319.52 Mn |
| Sep 30, 2024 | 333.43 Mn |
| Jun 30, 2024 | 289.85 Mn |
| Mar 31, 2024 | 332.69 Mn |
| Dec 31, 2023 | 282.78 Mn |
| Sep 30, 2023 | 349.06 Mn |
| Jun 30, 2023 | 371.85 Mn |
| Mar 31, 2023 | 417.88 Mn |
| Dec 31, 2022 | 433.26 Mn |
| Sep 30, 2022 | 480.48 Mn |
| Jun 30, 2022 | 537.56 Mn |
| Mar 31, 2022 | 611.70 Mn |
| Dec 31, 2021 | 670.17 Mn |
| Dec 31, 2020 | 367.73 Mn |